XRCC2 and neoplasm: As shown in Figure S1, we observed increased expression levels in the tumor group for FANCA, BRCA2, FANCG, FANCM, SLX4, ERCC4, and FAAP100 (all p < 0.05), while a decreased level was observed for FANCB, FANCC, FANCD2, FANCE, FANCI, FANCL, RAD51C, RAD51, BRCA1, UBE2T, XRCC2, MAD2L2, and RFWD3 (all p < 0.05) compared with the normal group.